TherapeuticsMD Receives Approval from FDA on the Supplemental New Drug Application for the 0.5 mg/100mg Dose of the Company's BIJUVA Product

On December 28, 2021, TherapeuticsMD, Inc. received approval from the U.S. Food and Drug Administration (the FDA") on the supplemental New Drug Application for the 0.5 mg/100 mg dose of the Company's BIJUVA product. The Company is currently evaluating plans for commercialization of the low dosage BIJUVA product.